# Limited Competition: Clinical and Translational Science Award (CTSA) Program: Collaborative and Innovative Acceleration Award (UG3/UH3 Clinical Trial Optional)

Source: https://welltoldgrants.com/grants/par-22-167-limited-competition-clinical-and-translational-science/  
Official notice: https://www.grants.gov/search-results-detail/340192

> National Institutes of Health offered grants to colleges and universities. Applications closed on October 17, 2024.

| Field | Value |
|---|---|
| Opportunity number | PAR-22-167 |
| Agency | National Institutes of Health |
| Status | Forecast |
| Deadline | October 17, 2024 |
| Award ceiling | not stated |
| Award floor | not stated |
| Expected awards | not stated |
| Total funding | not stated |
| Cost sharing | not required |
| Assistance Listings | 93.121, 93.307, 93.313, 93.350, 93.846, 93.859, 93.865 |

## Who can apply

- Public and State controlled institutions of higher education

Other Eligible Applicants include the following: Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.

## What the grant funds

The Clinical and Translational Science Award (CTSA) Program Collaborative and Innovative Acceleration Award (CCIA) supports synergistic activities that accelerate the translational research process through collaboration and innovation. This funding opportunity announcement (FOA) invites applications to develop, demonstrate and disseminate innovative solutions to transform the field of translational science by addressing the inefficiencies that are common across diseases and bringing more interventions to all people more quickly through collaborative science among the CTSA Program hubs, NIH Institutes, Centers, Offices (ICOs) and/or external stakeholders.

## Questions people ask

### Is PAR-22-167 still open?

No. It closed on October 17, 2024. A newer notice is open: PAR-25-296, due dates in the notice, expires October 19, 2027.

### Who can apply for Limited Competition: Clinical and Translational Science Award (CTSA) Program: Collaborative and Innovative Acceleration Award (UG3/UH3 Clinical Trial Optional)?

National Institutes of Health accepted applications from colleges and universities. The notice adds further conditions, so read its eligibility section.

### What is the deadline for Limited Competition: Clinical and Translational Science Award (CTSA) Program: Collaborative and Innovative Acceleration Award (UG3/UH3 Clinical Trial Optional)?

Closed October 17, 2024. Applications are no longer accepted; the program's newer notices are on this page when there are any.

### Who has been funded under PAR-22-167?

NIH RePORTER lists 4 projects funded under PAR-22-167 in fiscal 2023 to 2026, at 3 institutions. The most were at State University of New York at Buffalo, Wake Forest University Health Sciences, University of Illinois at Chicago.

### Who has won Oral Diseases and Disorders Research grants before?

The largest recipients over five fiscal years were Regents of the University of Michigan, The Regents of the University of California, San Francisco, University of Southern California. The program made 2,263 awards worth $1.9 billion in that time.